Advertisement

Topics

Search Results for "Human Growth Hormone And Ptsd"

22:29 EDT 30th April 2017 | BioPortfolio

Matching Channels

Growth hormone GH

Somatropin Hgh rDNA Pfizer

What is GENOTROPIN? GENOTROPIN (somatropin [rDNA origin] for injection) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference i...

EGF receptor Mab human rDNA Amgen

Luteinizing hormone LH and folliclestimulating hormone FSH

Follicle stimulating hormone FSH

Follicle-stimulating hormone (FSH) now has become an established means of ovulation induction (OI) as part of assisted reproductive technology (ART). FSH is used to induce development of multiple foll...

Matching News

OPKO weekly growth hormone jab fails in phase 3

US biotech OPKO Health has said it will continue with clinical development of its long-acting human growth hormone product (hGH-CTP), even though it has failed in a late stage trial in adult growth ho...

Longer-Acting Growth Hormones Promising for Adult GH Deficiency

Growth hormone derivative somapacitan and recombinant human growth hormone somavaratan both produce data suggesting weekly or even biweekly dosing is safe and effective. Medscape Medical News

Growth Hormone May Be Novel Therapy for Very Rare Bone Disease

Recombinant human growth hormone (rhGH) is a potential novel therapy for fibrogenesis imperfecta ossium (FIO), a very rare but disabling and ultimately fatal bone disease, a small study from India sug...

Growth hormone could be filed without further trials, says OPKO

OPKO Health’s weekly growth hormone injection could be approvable in adults without need for further clinical trials, the company has told pharmaphorum. The biotech has worked with Pfizer to co-dev...

Medical News Today: Estrogen regulates the brain's fear response, protecting against PTSD

A new study examines how the sex hormone estrogen affects gene regulation in the brain, affecting the formation of fear memories and PTSD.

Oxytocin Being Tested for Treatment of PTSD and Alcohol Abuse

NewsA new trial may hold new hope for military personnel through treatment with oxytocin, sometimes referred to as the “love hormone.”

OPKO Health GHD Candidate Fails Phase III Trial

OPKO Health said today that the long-acting human growth hormone candidate hGH-CTP, which is being developed in adults with growth hormone deficiency under a collaboration with Pfizer, has failed a Ph...

Growth Hormone Enhances Anaerobic Capacity

Growth hormone replacement therapy may help improve physical function and quality of life among GH-deficient adults. Clinical Endocrinology

Matching PubMed Articles

Comparative pharmacokinetic and pharmacodynamic evaluation between a new biosimilar and reference recombinant human growth hormone.

To extend available dosing options in the treatment of growth hormone deficiency, a comparative pharmacokinetic and pharmacodynamic phase-1 clinical study involving subcutaneous administration of grow...

Oral delivery of human growth hormone: Preparation, characterization, and pharmacokinetics.

Daily subcutaneous injection of human growth hormone has been used for the treatment of growth hormone deficiency and growth failure but has led to poor patient compliance and renal toxicity. Thus, it...

Pharmacokinetic and Pharmacodynamic Modeling of MOD-4023, a Long-Acting Human Growth Hormone, in Growth Hormone Deficiency Children.

MOD-4023 is a long-acting human growth hormone (hGH) in clinical trials for the treatment of growth hormone deficiency (GHD). A key goal is maintenance of serum concentrations of insulin-like growth f...

Safety and PK/PD correlation of TV-1106, a recombinant fused human albumin-growth hormone, following repeat dose administration to monkeys.

TV-1106 is a recombinant human albumin genetically fused to growth hormone which is intended to reduce the frequency of injections for GH therapy users. We report the safety, tolerability, pharmacokin...

First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I.

This study is a first time assessment of safety and tolerability, pharmacokinetics, and pharmacodynamics of RO5046013 in human, in comparison with unmodified rhIGF-I.

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement